Safety of propylene glycol-free melphalan combined with carmustine, etoposide, and cytarabine in patients with non-Hodgkin lymphoma or Hodgkin lymphoma undergoing autologous stem cell transplantation

Trial Profile

Safety of propylene glycol-free melphalan combined with carmustine, etoposide, and cytarabine in patients with non-Hodgkin lymphoma or Hodgkin lymphoma undergoing autologous stem cell transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2016

At a glance

  • Drugs Melphalan (Primary) ; Carmustine; Cytarabine; Etoposide
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jan 2016 New trial record
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Jun 2015 Recruitment completed according to results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top